Received Aug 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | H7RF2 | — |
As of today, the patient received the second dose/ late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 47-year-old female patient who received HAB (Twinrix) (batch number H7RF2, expiry date 07-JAN-2026) for prophylaxis. Previously administered products included Twinrix (received first dose in September 2024). On 13-AUG-2025, the patient received the 2nd dose of Twinrix. On 13-AUG-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: As of today, the patient received the second dose/ late second dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-AUG-2025 The Vaccine Administration Facility was the same as Primary Reporter A pharmacist called to get guidance for the Twinrix vaccine series A female patient received the first dose back in September 2024 and as of today, the patient received the second dose which led to drug dose administration interval too long The pharmacist wanted to know how to proceed for the schedule of the third dose and when do they give her the third dose.